BOEHRINGER INGELHEIM and ViraTherapeutics announced a long-term collaboration to develop a next-generation oncolytic virus therapy platform and to investigate the ViraTherapeutics lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) alone and in combination with other therapies. ViraTherapeutics has developed its technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund and...
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
